For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Regenerx Biopharmaceuticals, Inc.

USPTO Granted Patents = 12

CIPO Patents = 8

EPO Patents = 3

Forward Citations = 16

Loading Chart...

Loading Chart...

13 inventors (with patents filed for the assignee):

Allan L Goldstein (9 out of 24 patents)

David Crockford (6 out of 9 patents)

Gabriel Sosne (3 out of 4 patents)

4. Jack Finkelstein, Jr (2 out of 2 patents)

5. Christian B Allan (1 out of 19 patents)

6. Michelle Wheater (1 out of 1 patent)

7. Hynda K Kleinman (1 out of 6 patents)

8. Katherine M Malinda (1 out of 4 patents)

9. William H Walton (1 out of 3 patents)

10. Jack Jr Finkelstein (0 patent)

11. Jack Finkelstein (0 patent)

12. JJ Finkelstein (0 patent)

12 patents: Sort by Forward Citations

1. 10004785 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2018-06-26),

2. 9821030 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2017-11-21),

3. 9585941 - Eye drop formulation (2017-03-07),

4. 9504730 - Method of achieving a thymosin beta 4 concentration in a human patient (2016-11-29),

5. 9056087 - Methods of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogues, isoforms and other derivatives (2015-06-16),

6. 8716215 - Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease (2014-05-06),

7. 8426365 - Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure (2013-04-23),

8. 8399609 - Treating or preventing extracellular matrix build-up (2013-03-19),

9. 8399412 - Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating NF-kappabeta or supressing NF-kappabeta-mediated actions (2013-03-19),

10. 8383576 - LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized (2013-02-26),

11. 8143218 - Treatment of skin, and wound repair, with thymosin beta 4 (2012-03-27),

12. 8093214 - Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure (2012-01-10),

RegeneRX Biopharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutic products for tissue regeneration and repair. With a dedicated team of scientists, RegeneRX is actively engaged in research and development of novel drug candidates aimed at treating various conditions, including ophthalmic, cardiac, and respiratory disorders. Through their pioneering approach, RegeneRX aims to provide cutting-edge solutions that improve patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

12 Patents

#48 in Rockville, MD

#333 in Maryland

#24,779 in US

#46,665 in the World

Rockville, MD, United States of America

Regenerx Biopharmaceuticals, Inc.

Forward Citations = 16

13 inventors:

Allan L Goldstein (9 out of 24 patents)

David Crockford (6 out of 9 patents)

Gabriel Sosne (3 out of 4 patents)

4. Jack Finkelstein, Jr (2 out of 2 patents)

5. Christian B Allan (1 out of 19 patents)

Please report any incorrect information to support@idiyas.com

Loading…